01 8Vesicare
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 305
2019 Revenue in Millions : 520
Growth (%) : -41
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 209
2020 Revenue in Millions : 303
Growth (%) : -26
Main Therapeutic Indication : Nephrology
Currency : USD
2022 Revenue in Millions : 130
2021 Revenue in Millions : 211
Growth (%) : -39
Main Therapeutic Indication : Overactive Bladder
Currency : USD
2015 Revenue in Millions : 1,178
2014 Revenue in Millions : 1,190
Growth (%) : 1%
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 884
2017 Revenue in Millions : 885
Growth (%) : -0.10%
Main Therapeutic Indication : Urology
Currency : USD
2016 Revenue in Millions : 1,081
2015 Revenue in Millions : 1,222
Growth (%) : -12
Main Therapeutic Indication : Renal Disorders
Currency : USD
2017 Revenue in Millions : 944
2016 Revenue in Millions : 1,153
Growth (%) : -18
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 528
2018 Revenue in Millions : 913
Growth (%) : -42
